NewsOur news NewsBioVersys presents latest data on clinical pipeline at ECCMID 2021NewsBioVersys appoints Medical Director and Head of CMCNewsBioVersys receives a second CARB-X award of up to US$ 15.34 million for BV300NewsMartin Bott appointed CFO of BioversysNewsBioVersys receives €20 million in EU financing to support development of new antibioticsNewsBioVersys, TASK and GSK receive 2.7 million euro from EDCTP for Phase 2a clinical trialNewsBioVersys Announces First Subjects Dosed in Phase 1 Clinical Trial of BVL-GSK098NewsBioVersys announces first subjects dosed in phase 1 clinical trial of BV100BioVersys in the NewsInnovation im Kampf gegen eine schleichende Pandemie 123…56Next »